Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has begun the process to start phase II trials for Xantryl to treat psoriasis and later eczema, and is anticipating starting one of the trials later this year.
Subscribe to our email newsletter
Provectus is preparing the FDA filing to commence the trials and expects to begin clinical studies for psoriasis in late 2005 and eczema in 2006. The company has successfully completed preclinical and phase I studies, in Denmark and the US, for the treatment of psoriasis with Xantryl.
Provectus CEO Dr Craig Dees said, “We are extremely pleased to begin the process of moving this drug through the regulatory steps using clinical applications that we hope will lend themselves to rapid approval and market introduction. There are more than seven million patients in the US alone who suffer from psoriasis, many of whom have given up on an effective treatment.”
“In addition,” Dees continued, “certain products currently prescribed for treating eczema are now required to carry warnings that they might produce cancer as a side effect, creating an opportunity for Xantryl as it may be shown to be a side-effect free therapy for these patients.”